Statins in homozygous familial hypercholesterolemia
- 289 Downloads
Homozygous familial hypercholesterolemia is a rare disorder resulting in severe premature atherosclerosis. Drug therapy was previously viewed as inadequate for control of the dyslipidemia, so portacaval shunting, plasmapheresis, and liver transplantation were undertaken to treat this condition. Despite these drastic measures, additional cholesterol-lowering treatment may still be required. Furthermore, there is a need for pharmacologic control until additional measures can be undertaken. The statins, an evolving class of cholesterol-modifying drugs, represent a significant development in the treatment of homozygous familial hypercholesterolemia. The experience with statins in this condition is limited, but some insight into their utility has been gained from studies reviewed in this article. It is recommended that high doses of statins be used in combination with other lipid-modifying strategies for the best control of the dyslipidemia of homozygous familial hypercholesterolemia.
KeywordsAtorvastatin Probucol Homozygous Familial Hypercholesterolemia Homozygous Familial Hypercholesterolaemia Avasimibe
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 4.Thompson GR, Ford J, Jenkinson M, Trayner I: Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia. QJM 1986, 232:803–811.Google Scholar
- 7.Rubinsztein DC, Raal FJ, Seftel HC, et al.: Characterization of six patients who are double hetrozygotes for familial hypercholesterolaemia and familial defective Apo B-100. Arterioscler Thromb Vasc Biol 1993, 13:1076–1081.Google Scholar
- 9.März W, Baumstark MW, Scharnagl H, et al.: Accumulation of “small dense” low density lipoproteins (LDL) in a homozygous patient with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. J Clin Invest 1993, 92:2922–2933.PubMedCrossRefGoogle Scholar
- 11.Goldstein J, Hobbs HH, Brown MS: Familial hypercholesterolaemia. In The Metabolic and Molecular Basis of Inherited Disease. Edited by Scriver A, Beadet W, Sly S, Valle D. New York: McGraw-Hill; 1995:1981–2030.Google Scholar
- 12.Mahley RW, Ji Z: Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein. Eur J Lipid Res 1999, 40:1–16.Google Scholar
- 15.Farnier M, Stein E, Megnien S, et al.: Efficacy and Safety of Implitapide, a Microsomal Triglyceride Transfer Protein Inhibitor in Patients with Primary Hypercholesterolemia. XIV International Symposium on Drugs Affecting Lipid Metabolism 2001. New York: Giovanni Lorenzini Medical Foundation; 2001:46.Google Scholar
- 31.Ratanjee BD, Raal FJ, Firth JC, Marais AD: Atorvastatin lowers plasma cholesterol in homozygotes for familial hypercholesterolaemia after porto-systemia shunt operations and independently of serum bile acid concentration. Lipid Atherosclerosis Soc S Afr 1998, 23.Google Scholar
- 32.Klepack E, Raal FJ, Marais AD, Heinonen T: Effects Of Avasimibe in Patients with Severe Hypercholesterolemia.XIV International Symposium on Drugs Affecting Lipid Metabolism 2001. New York: Giovanni Lorenzini Medical Foundation; 2001:107.Google Scholar
- 33.Gylling H, Miettinen TA: Serum Plant Sterol Levels On and Off Statin Treatment and Stanol vs Sterol Ester Consumption in a Homozygous Form of Familial Hypercholesterolemia.XIV International Symposium on Drugs Affecting Lipid Metabolism 2001. New York: Giovanni Lorenzini Medical Foundation; 2001:31.Google Scholar